Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

Area of Science:

• Rheumatology and Immunology
• Oncology
• Clinical Medicine

Background:

• Polymyalgia rheumatica immune-related adverse events (ICI-PMRs) are a newly identified condition.
• ICI-PMR shares clinical, laboratory, and imaging features with classical polymyalgia rheumatica (PMR).
• Unanswered questions persist regarding the differentiation of ICI-PMR from classical PMR and other conditions.

Purpose of the Study:

• To highlight the distinct nature of ICI-PMR despite similarities to classical PMR.
• To address the challenges in differentiating ICI-PMR from classical PMR and mimics.
• To explore the potential of ICI-PMR as a model for induced PMR.

Main Methods:

• Comparative analysis of clinical, laboratory, and imaging data.
• Review of existing literature on ICI-PMR and classical PMR.
• Discussion of therapeutic strategies and implications.

Main Results:

• ICI-PMR is a novel entity with similarities to classical PMR.
• Differentiating ICI-PMR from classical PMR and other conditions remains complex.
• Current treatment for ICI-PMR is based on classical PMR guidelines with immunotherapy considerations.

Conclusions:

• ICI-PMR represents a distinct condition requiring careful differentiation.
• Further research into ICI-PMR may provide insights into classical PMR.
• ICI-PMR could serve as a valuable model for understanding induced PMR and its treatment.